– USA, CA – Meliora Therapeutics, a machine learning therapeutics company developing novel and transformative cancer drugs, announced the appointment of Dieter Weinand as Chairman of the Board of Directors, and the appointment of Jean-Jacques Bienaimé as Independent Director.
“We are thrilled to have Dieter Weinand and Jean-Jacques Bienaimé join Meliora’s Board of Directors. Their expertise and leadership in drug development will be incredible assets to our company. I look forward to working closely with both to further Meliora’s vision of being the world’s leading machine learning oncology therapeutics company,” said co-founder and CEO, David Li.
About Dieter Weinand
Dieter Weinand is an experienced business leader with over 30 years of experience in the pharmaceutical industry and the former CEO and Chairman of the Board of Bayer Pharmaceuticals. During a career stretching back over 30 years, he has held various responsibilities in general management, commercial, operational, and strategic leadership roles, leading business operations in the Asia-Pacific region, Europe, the Middle East, Africa, Latin America, and the United States, for companies including Bayer, Pfizer, Bristol-Myers Squibb, and Sanofi.
He has also led the development, launch, and commercialization of products in various therapeutic areas, including cardiovascular diseases, oncology, dermatology, immunology, and respiratory and inflammatory diseases. He is currently Chairman of the Board of Replimune, Umoja, and Inspirna, and Executive Chairman of the Board of Mnemo Therapeutics.
“I am very pleased to become Chairman of the Board for Meliora, a company which has the potential to make a significant clinical difference in cancer patients’ lives using its novel machine learning powered approach. I look forward to working together with David and the Meliora team to advance the company through its next stages of growth and to achieve its strategic business and pipeline objectives,” said Dieter Weinand.
Dieter Weinand earned an M.S. in pharmacology and toxicology from Long Island University, New York, and a B.A. in biology from Concordia College, New York.
About Jean-Jacques Bienaimé
Jean-Jacques Bienaimé has over three decades of experience in the biotechnology and pharmaceutical industries, most recently serving as Chairman and CEO of BioMarin Pharmaceuticals. He joined BioMarin in May 2005, when the company had a single marketed product and approximately $26 million in annual revenues. Under Mr. Bienaimé’s leadership, BioMarin grew significantly, from about 300 US-only employees to more than 3,400 people in almost 80 countries around the world and over $2.4 billion in sales in 2023. BioMarin received 8 drug approvals from the FDA during this period.
Before joining BioMarin, Mr. Bienaimé spent years in similar executive roles at other pharmaceutical and biotech companies and currently serves on the board of directors for Incyte, Immunome, Owkin, and Keros.
“I am excited to join the Meliora Board of Directors as they endeavor to bring transformative oncology therapeutics to the patients most in need through their ML-powered approach,” said Jean-Jacques Bienaimé. “In my career, focusing on patients while leveraging the latest technology has been critical to success, and Meliora is highly aligned in this approach. I look forward to enhancing Meliora’s ability to execute on its compelling vision.”
Jean-Jacques Bienaimé studied economics at the École de Commerce de Paris and received an M.B.A from the University of Pennsylvania.
About Meliora Therapeutics
Meliora Therapeutics is discovering and developing small molecule oncology therapies for high-value cancer targets with its proprietary machine learning-powered platform, AnchorOmics. Pairing the first multimodal, mechanism-of-action machine learning algorithm and a world-class team of scientists and engineers, Meliora is pioneering a novel approach to create life-changing therapies for cancer patients. San Francisco and Cambridge-based Meliora Therapeutics has raised $11 million to date and is led by leaders from the fields of AI, biotechnology, and drug discovery.
For more information: https://www.melioratx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.